We have observed
4 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after June 20, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
Pharmaceutical compositions comprising an acid salt
Immediate release tablets of rasagiline hemitartrate
Pharmaceutical composition comprising almotriptan malate having uniform drug distribution and potency
Stable pharmaceutical compositions with fast onset